$AUTL

Autolus Therapeutics plc

Autolus Therapeutics is a biopharmaceutical company that develops, manufactures and delivers programmed T cell therapies for cancer and autoimmune diseases. Its commercial product, AUCATZYL (obe-cel), is an autologous CD19 CAR T cell therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus launched AUCATZYL in the United States in January 2025 and in the United Kingdom in January 2026. It manufactures the product at the Nucleus, its commercial manufacturing site in Stevenage, U.K.; Cardinal Health 105, LLC is its U.S. distribution partner. Autolus also develops obe-cel for pediatric B-cell cancers and autoimmune conditions, including lupus and progressive multiple sclerosis, and has other clinical-stage T cell programs. It makes money through commercialization of AUCATZYL and retains worldwide commercial rights to the product. Autolus is headquartered in London, United Kingdom.

2
0
0

No SEC Form 4 filings for $AUTL in the last 30 days.

See all $AUTL insider activity →
Med

Syncona H1 2026 presentation: Beacon drives NAV gain, M&A tailwinds build

Syncona Ltd reported a 3.0% NAV increase for H1 2026, driven by Beacon Therapeutics' clinical data and M&A tailwinds. 92% of its £921M portfolio is in clinical-stage or commercial companies, with a 39.9% share price gain. Portfolio companies attracted £220M in investments, and Syncona expects further value inflection points.

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL®…

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026

AUTL sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AUTL (Autolus Therapeutics plc). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent AUTL coverage spans earnings, financial news and technology.

What's driving AUTL

AlphAI scores every news story that mentions AUTL with an AI model for sentiment and relevance, and aggregates insider trades from Autolus Therapeutics plc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AUTL

Score
$AUTLHighEarnings

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL®…

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus Therapeutics (AUTL) reported Q2 2026 revenue of $45.7M, up 119% YoY, driven by AUCATZYL sales. The company raised full-year guidance to $140M-$150M and secured a $250M credit facility. Despite improved margins, Autolus posted a $39.1M net loss and cash decreased to $201.6M. AUCATZYL carries significant safety warnings, and $150M of financing is tied to revenue milestones.

$AUTLMedAI 8/10

Autolus (AUTL) Q2 2026 Earnings Call Transcript

Autolus (AUTL) reported Q2 2026 net product revenue of $45.7M, up 119% YoY, and raised full-year guidance to $140M-$150M. Gross margin improved to 55%, and cash runway extends into Q2 2028. The company expanded treatment centers and saw initial U.K. sales.

Related tickers